Development and validation of an iPad-based Japanese language monosyllable speech perception test (iCI2004 monosyllable).


Journal

Acta oto-laryngologica
ISSN: 1651-2251
Titre abrégé: Acta Otolaryngol
Pays: England
ID NLM: 0370354

Informations de publication

Date de publication:
Mar 2021
Historique:
pubmed: 16 12 2020
medline: 29 10 2021
entrez: 15 12 2020
Statut: ppublish

Résumé

Speech perception tests are commonly used as indices reflecting hearing ability in daily life. In Japan, the CI-2004 test, first developed in 2004, is widely used as standard, but it was not validated against a large number of normal hearing controls and hearing loss patients. The primary objective of the present study was to develop and validate iPad-based software for the Japanese monosyllable speech perception test, 'iCI2004'. Seven universities and two medical centers participated in this study. The hearing threshold and Japanese monosyllable speech perception test results of 77 people with normal hearing and 459 people with hearing loss were collected. All participants with normal hearing achieved almost perfect perception results both in quiet and in noise. For cochlear implant users, the average monosyllable speech perception score was 55.1 ± 19.6% in quiet and 40.3 ± 19.2% in noise (SNR + 10dB). We developed iPad-based Japanese monosyllable speech perception test software and validated it by testing a large number of controls and hearing loss patients with cochlear implants or hearing aids. The developed monosyllable speech perception test has a sufficiently large dynamic range for assessing improvement in speech perception in Japanese cochlear implant users.

Sections du résumé

BACKGROUND BACKGROUND
Speech perception tests are commonly used as indices reflecting hearing ability in daily life. In Japan, the CI-2004 test, first developed in 2004, is widely used as standard, but it was not validated against a large number of normal hearing controls and hearing loss patients.
AIMS/OBJECTIVES OBJECTIVE
The primary objective of the present study was to develop and validate iPad-based software for the Japanese monosyllable speech perception test, 'iCI2004'.
MATERIAL AND METHODS METHODS
Seven universities and two medical centers participated in this study. The hearing threshold and Japanese monosyllable speech perception test results of 77 people with normal hearing and 459 people with hearing loss were collected.
RESULTS RESULTS
All participants with normal hearing achieved almost perfect perception results both in quiet and in noise. For cochlear implant users, the average monosyllable speech perception score was 55.1 ± 19.6% in quiet and 40.3 ± 19.2% in noise (SNR + 10dB).
CONCLUSIONS AND SIGNIFICANCE CONCLUSIONS
We developed iPad-based Japanese monosyllable speech perception test software and validated it by testing a large number of controls and hearing loss patients with cochlear implants or hearing aids. The developed monosyllable speech perception test has a sufficiently large dynamic range for assessing improvement in speech perception in Japanese cochlear implant users.

Identifiants

pubmed: 33320029
doi: 10.1080/00016489.2020.1853229
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-272

Auteurs

Shin-Ya Nishio (SY)

Department of Hearing Implant Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.

Tetsuya Tono (T)

Department of Otolaryngology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, Japan.
Audiology and Hearing Implant Center in University of Miyazaki Hospital, Kiyotake-cho, Miyazaki, Japan.

Takako Iwaki (T)

Department of Medical Sciences, Major of Communication Disorders and Sciences, Faculty of Health and Medical Sciences, Aichi Shukutoku University, Nagakute, Japan.

Hideaki Moteki (H)

Department of Hearing Implant Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.

Kumiko Suzuki (K)

Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.

Yui Tsushima (Y)

Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.

Akinori Kashio (A)

Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, The University of Tokyo, Japan.

Yusuke Akamatsu (Y)

Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, The University of Tokyo, Japan.

Hiroaki Sato (H)

Department of Otolaryngology, Iwate Medical University, Morioka, Japan.

Keiko Yaegashi (K)

Department of Otolaryngology, Iwate Medical University, Morioka, Japan.

Hidehiko Takeda (H)

Department of Otolaryngology, Toranomon Hospital, Tokyo, Japan.

Fumiai Kumagai (F)

Department of Otolaryngology, Toranomon Hospital, Tokyo, Japan.

Takahiro Nakashima (T)

Department of Otolaryngology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, Japan.
Audiology and Hearing Implant Center in University of Miyazaki Hospital, Kiyotake-cho, Miyazaki, Japan.

Yusuke Matsuda (Y)

Department of Otolaryngology, Faculty of Medicine, University of Miyazaki, Kiyotake-cho, Japan.
Audiology and Hearing Implant Center in University of Miyazaki Hospital, Kiyotake-cho, Miyazaki, Japan.
Department of Otolaryngology, Kagoshima City Hospital, Kagoshima, Japan.

Naohito Hato (N)

Department of Otolaryngology Ehime University School of Medicine, Shitsukawa, Japan Ehime.

Teppei Dairoku (T)

Department of Otolaryngology Ehime University School of Medicine, Shitsukawa, Japan Ehime.

Masae Shiroma (M)

Department of Speech and Hearing Sciences, International University of Health and Welfare Graduate School, Tokyo, Japan.

Ryosuke Kawai (R)

MED-EL Japan Co. Ltd, Chiyoda-ku, Japan.

Shin-Ichi Usami (SI)

Department of Hearing Implant Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH